News

2022 Jul 13

Dr. Steven Josefowicz Honored with Pathogenesis of Infectious Disease Award

Dr. Steven Josefowicz , an assistant professor in the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine, has won a 2022 Investigators in the Pathogenesis of Infectious Disease (PATH) award from the... Read more

2022 Jun 30

In Brief: Surgery May be Avoided for Children with Rare Skull Tumor

Surgery can usually be avoided in children with a rare tumor of the skull, based on new research by investigators from Weill Cornell Medicine , NewYork-Presbyterian , Nicklaus Children’s Hospital , the University of Texas... Read more

2022 Jun 29

Weill Cornell Medicine Receives Cancer Grand Challenges Award Focused on Cachexia

Weill Cornell Medicine, Rutgers Cancer Institute of New Jersey and Cold Spring Harbor Laboratory have received a $25 million Cancer Grand Challenges award to tackle cancer cachexia, the debilitating wasting syndrome that is... Read more

Cancer cells, malignant cells, scientific 3D illustration

2022 Jun 29

In Brief: Treating Precancerous Anal Lesions Reduces Anal Cancer Risk by More Than Half in People with HIV

A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment. The ANCHOR study... Read more

closeup of doctor's hand writing in chart

2022 Jun 28

Mantle Cell Lymphoma Treatment Varies According to Setting

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators... Read more

2022 Jun 23

New Technology Helps Reveal Inner Workings of Human Genome

Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome,... Read more

2022 Jun 09

Cancer symposium fosters collaboration across Cornell

On May 19 and 20, researchers from Cornell University’s Ithaca and New York City campuses gathered at the Cornell College of Veterinary Medicine (CVM) for the third Intercampus Cancer Research Symposium. Returning after a... Read more

a woman in a white coat posing for a photo

2022 Jun 06

Dr. Sara Zaccara Honored with 2022 Tri-Institutional Breakout Award

Dr. Sara Zaccara, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has won a 2022 Tri-Institutional Breakout Award for Junior Investigators. Weill Cornell Medicine, Memorial Sloan... Read more

2022 Jun 03

2022 Biomedical Business Plan Challenge Showcases Promising Startups

A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge. The... Read more

3D rendering of a NK Cell (Natural Killer Cell) destroying a cancer cell

2022 Jun 02

Immune Therapy Targets Cells that Cause Leukemia Relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the... Read more

2022 May 31

Awards and Honors – May 31, 2022

Dr. Joseph J. Fins , chief of the Division of Medical Ethics, the E. William Davis Jr., M.D., Professor of Medical Ethics and a professor of medicine, was honored as an Honorary Doctor of Humane Letters at Wesleyan... Read more

2022 May 27

New Cancer Subtype May Illuminate Treatment Strategy

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its... Read more

2022 May 25

Study Reveals Cause, Potential Precision Therapies for Aggressive Type of Lymphoma

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people... Read more

2022 May 15

Benefits of PSA Prostate Cancer Screening Found to Be More Favorable than Previous Estimates, Especially for Blacks

New research led by investigators from Weill Cornell Medicine, Fred Hutchinson Cancer Center, University Hospitals Cleveland and Case Western Reserve University found that prostate cancer screening with the prostate specific... Read more

2022 May 09

Tumor Release of Lactate Forces Nearby Cells into Supportive Role

Tumors can force neighboring cells into supporting cancer growth by releasing lactate into their local environment, according to researchers at Weill Cornell Medicine. The findings pave the way for future drug treatments... Read more

2022 May 09

T Cell Behavior Determines Which Tumors Respond to Treatment

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why. When immune cells called T lymphocytes infiltrate... Read more

2022 May 04

Advance in Understanding Cell Division Could Lead to New Cancer Treatments

A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the... Read more

a doctor giving results to a patient who is out of the shot

2022 Apr 22

Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases

Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate... Read more

2022 Apr 13

Tumors Change Their Metabolism to Spread More Effectively

Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill... Read more

2022 Mar 16

A Potential New Target for Cancer Immunotherapies

Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and... Read more